| scholarly article | Q13442814 |
| P50 | author | Carl D. Langefeld | Q102208371 |
| Pamela J Hicks | Q111585264 | ||
| Meredith A Bostrom | Q114332902 | ||
| Barry Freedman | Q67485116 | ||
| Cheryl A Winkler | Q87782749 | ||
| Jasmin Divers | Q89813877 | ||
| Donald W Bowden | Q92206005 | ||
| Jeffrey B. Kopp | Q38359650 | ||
| Yongmei Liu | Q67422669 | ||
| P2093 | author name string | George W Nelson | |
| Mary E Cunningham | |||
| P2860 | cites work | Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group | Q69167761 |
| Renal insufficiency in treated essential hypertension | Q69956789 | ||
| Blood pressure and end-stage renal disease in men | Q71574790 | ||
| Renal biopsy findings in presumed hypertensive nephrosclerosis | Q72173122 | ||
| Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for nephropathy | Q80471061 | ||
| A note on exact tests of Hardy-Weinberg equilibrium | Q24531633 | ||
| A High-Density Admixture Map for Disease Gene Discovery in African Americans | Q24533390 | ||
| MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis | Q24643421 | ||
| MYH9 is associated with nondiabetic end-stage renal disease in African Americans | Q24653027 | ||
| Haploview: analysis and visualization of LD and haplotype maps | Q27860955 | ||
| Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis | Q28145757 | ||
| Genotype-phenotype correlation in MYH9-related thrombocytopenia | Q33367809 | ||
| Estimation of individual admixture: analytical and study design considerations | Q34394604 | ||
| TRPC6 and FSGS: the latest TRP channelopathy | Q34622852 | ||
| Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans | Q34774598 | ||
| Familial clustering of chronic kidney disease | Q36842851 | ||
| Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton | Q36931220 | ||
| Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study | Q37359254 | ||
| Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower | Q39722492 | ||
| The link between hypertension and nephrosclerosis | Q40586621 | ||
| Clinical documentation of end-stage renal disease due to hypertension | Q40747330 | ||
| Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial | Q43626458 | ||
| Hypertensive nephrosclerosis in African Americans versus Caucasians | Q44039626 | ||
| Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension | Q44839105 | ||
| Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population | Q45149880 | ||
| Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators | Q46250134 | ||
| Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group | Q46278015 | ||
| The familial risk of end-stage renal disease in African Americans | Q46726027 | ||
| Identification of podocin (NPHS2) gene mutations in African Americans with nondiabetic end-stage renal disease | Q46958377 | ||
| Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis | Q64459160 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | arterial hypertension | Q41861 |
| kidney disease | Q1054718 | ||
| P304 | page(s) | 736-745 | |
| P577 | publication date | 2009-01-28 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Polymorphisms in the non-muscle myosin heavy chain 9 gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans | |
| P478 | volume | 75 |
| Q28740367 | A genome-wide association search for type 2 diabetes genes in African Americans |
| Q28943287 | A genome-wide association study for diabetic nephropathy genes in African Americans |
| Q33540002 | A meta-analysis of genome-wide data from five European isolates reveals an association of COL22A1, SYT1, and GABRR2 with serum creatinine level |
| Q27022275 | APOL1 and nephropathy progression in populations of African ancestry |
| Q51492603 | APOL1 variants and kidney disease in people of recent African ancestry. |
| Q37467503 | Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. |
| Q24602407 | African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans |
| Q35567885 | African origins and chronic kidney disease susceptibility in the human immunodeficiency virus era. |
| Q33623998 | Analysis of coding variants identified from exome sequencing resources for association with diabetic and non-diabetic nephropathy in African Americans |
| Q30501039 | Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model |
| Q24621889 | Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans |
| Q35468728 | Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans |
| Q37809770 | Arrest of the true culprit and acquittal of the innocent? Genetic revelations charge APOL1 variants with kidney disease susceptibility |
| Q55019060 | Assessing known chronic kidney disease associated genetic variants in Saudi Arabian populations. |
| Q35675334 | Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites |
| Q34169649 | Association of polymorphisms in the klotho gene with severity of non-diabetic ESRD in African Americans |
| Q36826342 | Association of the receptor for advanced glycation end-products (RAGE) gene polymorphisms in Malaysian patients with chronic kidney disease |
| Q24606581 | Association of trypanolytic ApoL1 variants with kidney disease in African Americans |
| Q37593685 | Blood pressure level and kidney disease progression: do we really need to go to 130/80 mm Hg? |
| Q35130219 | Candidate genes for non-diabetic ESRD in African Americans: a genome-wide association study using pooled DNA. |
| Q37261346 | Characteristics of uninsured Americans with chronic kidney disease |
| Q33773661 | Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. |
| Q26999279 | Developments in renal pharmacogenomics and applications in chronic kidney disease |
| Q45072634 | Diabetic Microvascular Disease: An Endocrine Society Scientific Statement |
| Q57877162 | Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey |
| Q21144945 | Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans |
| Q33785127 | Effect of community characteristics on familial clustering of end-stage renal disease |
| Q35210244 | Effects of race on albuminuria and risk of cardiovascular and kidney disease |
| Q37809748 | Epidemiology of hypertensive kidney disease |
| Q33997784 | Essential hypertension and risk of nephropathy: a reappraisal |
| Q61905288 | Estimated glomerular filtration rate (eGFR), 25(OH) D3, chronic kidney disease (CKD), the MYH9 (myosin heavy chain 9) gene in old and very elderly people |
| Q34556186 | Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications |
| Q60194447 | Fetal-Not Maternal-APOL1 Genotype Associated with Risk for Preeclampsia in Those with African Ancestry |
| Q38192853 | Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist |
| Q44562858 | Gene polymorphism of vascular endothelial growth factor -1154 G>A is associated with hypertensive nephropathy in a Hispanic population. |
| Q33621421 | Gene-gene and gene-environment interactions in HIV-associated nephropathy: A focus on the MYH9 nephropathy susceptibility gene |
| Q27024548 | Genetic and epigenetic factors influencing chronic kidney disease |
| Q35675247 | Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy |
| Q34018541 | Genetic basis of nondiabetic end-stage renal disease |
| Q36925161 | Genetic contribution and associated pathophysiology in end-stage renal disease |
| Q28657760 | Genetic variation and adaptation in Africa: implications for human evolution and disease |
| Q33821365 | Genetics of focal segmental glomerulosclerosis and human immunodeficiency virus-associated collapsing glomerulopathy: the role of MYH9 genetic variation |
| Q37781545 | Genome-Wide Association Studies in Nephrology Research |
| Q46040078 | Genome-wide linkage analysis of serum creatinine in three isolated European populations. |
| Q34803998 | Genomewide linkage scan for diabetic renal failure and albuminuria: the FIND study |
| Q37802413 | Hereditary kidney diseases: highlighting the importance of classical Mendelian phenotypes |
| Q38074565 | How benign is hematuria? Using genetics to predict prognosis |
| Q26851271 | Hypertension and chronic kidney disease: controversies in pathogenesis and treatment |
| Q34131899 | Hypertensive nephropathy: prevention and treatment recommendations |
| Q33847247 | Inferring genetic ancestry: opportunities, challenges, and implications |
| Q30248678 | Insights into kidney diseases from genome-wide association studies |
| Q33828986 | Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report |
| Q45377385 | Is there a genetic basis for health disparities in human immunodeficiency virus disease? |
| Q33873191 | Kidney transplantation in a low-resource setting: Nigeria experience |
| Q37045873 | Lifetime incidence of CKD stages 3-5 in the United States |
| Q35128320 | MYH9 and APOL1 gene polymorphisms and the risk of CKD in patients with lupus nephritis from an admixture population |
| Q34990741 | MYH9 genetic variants associated with glomerular disease: what is the role for genetic testing? |
| Q38261393 | Macrophage migration inhibitory factor -173G/C gene polymorphism increases the risk of renal disease: a meta-analysis |
| Q35745738 | Meta-analysis of genome-wide linkage scans for renal function traits |
| Q24632288 | Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene |
| Q38130063 | Nephrology in Africa--not yet uhuru |
| Q35282729 | Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting |
| Q89501822 | Non-diabetic end-stage renal disease in Saudis associated with polymorphism of MYH9 gene but not UMOD gene |
| Q34021318 | Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD |
| Q53093479 | Non-muscle myosin-IIA is critical for podocyte f-actin organization, contractility, and attenuation of cell motility. |
| Q90171195 | Novel Haplotype Indicator for End-Stage Renal Disease Progression among Saudi Patients |
| Q41988586 | Pilot study of an association between a common variant in the non-muscle myosin heavy chain 9 (MYH9) gene and type 2 diabetic nephropathy in a Taiwanese population. |
| Q37359254 | Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study |
| Q42686712 | Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with the progression of IgA nephropathy in Chinese |
| Q34058525 | Potential donor-recipient MYH9 genotype interactions in posttransplant nephrotic syndrome after pediatric kidney transplantation |
| Q34005215 | Potential effects of MYH9-associated nephropathy on dialysis and kidney transplant outcomes |
| Q33748130 | Precipitation of kidney myosin IIA and IIB by freezing |
| Q40962428 | Prevalence and Determinants of Chronic Kidney Disease Among Hypertensive Cameroonians According to Three Common Estimators of the Glomerular Filtration Rate. |
| Q39327805 | Prevalence of chronic kidney disease in hypertensive patients in ghana |
| Q37815082 | Problems with 'focal segmental glomerulosclerosis'. |
| Q34038082 | Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. |
| Q34362733 | Race, kidney disease progression, and mortality risk in HIV-infected persons |
| Q33875987 | Reappraisal of the impact of race on survival in patients on dialysis |
| Q34572458 | Recent developments in HIV-related kidney disease |
| Q35691378 | Recent progress in the genetics of diabetic microvascular complications. |
| Q28082365 | Renal autoregulation in health and disease |
| Q39395342 | Renalase gene polymorphism and epinephrine level in chronic kidney disease |
| Q38087486 | Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder |
| Q34169794 | Risk factors for progression of chronic kidney disease |
| Q35899141 | Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis |
| Q26866452 | Screening for chronic comorbid diseases in people with HIV: the need for a strategic approach |
| Q37929278 | Sickle cell nephropathy - a practical approach |
| Q35759686 | Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans |
| Q37616991 | Susceptibility genes in common complex kidney disease |
| Q35658743 | Target organ damage in African American hypertension: role of APOL1. |
| Q36365716 | The Association of African Ancestry and elevated creatinine in the Coronary Artery Risk Development in Young Adults (CARDIA) Study |
| Q64119111 | The Effects of Breviscapine Injection on Hypertension in Hypertension-Induced Renal Damage Patients: A Systematic Review and a Meta-Analysis |
| Q51422854 | The German Chronic Kidney Disease (GCKD) study: design and methods. |
| Q34994823 | The MYH9/APOL1 region and chronic kidney disease in European-Americans |
| Q37778202 | The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans |
| Q34092120 | The association of the MYH9 gene and kidney outcomes in American Indians: the Strong Heart Family Study |
| Q37895457 | The genetics of common kidney disease: a pathway toward clinical relevance. |
| Q35861466 | The new era of APOL1-associated glomerulosclerosis |
| Q34038096 | The non-muscle Myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans |
| Q34182007 | The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus |
| Q34012316 | The relationship of ethnicity to the prevalence and management of hypertension and associated chronic kidney disease |
| Q43981186 | The relative risk of overall graft loss and acute rejection among African American renal transplant recipients is attenuated with advancing age |
| Q34105121 | The spectrum of MYH9-associated nephropathy |
| Q34281425 | The state of U.S. living kidney donors |
| Q33762596 | Translating associations between common kidney diseases and genetic variation into the clinic |
Search more.